Abstract: This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) of Neisseria meningitidis in solutions containing fully synthetic variants of the GM3 ganglioside.

Abstract: The present disclosure relates to a device for the measurement of fluids and the prevention of infections caused by probes comprising a module of fluid measurement and a probe infection prevention module. The fluid measurement module comprises an electronic module for the measurement of the body fluids; a disposable container for temporary retention of fluid during measurement; a fluid circulation tube arranged between the probe and the disposable container; and a disposable bag for the final disposal of waste fluids. The probe infection prevention module comprises a sheet equipped with adhesive allowing conformation of a flexible structure to the skin or mucosa of the patient. This module incorporates a gel externally that prevents infections, as well as internal antimicrobial components to inhibit passage of microorganisms through the system. The present invention allows non-invasive measurement of fluids utilizing existing probes while contributing to the reduction of infections in patients.

Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.

Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.